Eintrag weiter verarbeiten
Verfügbar über Online-Ressource

The Effect of Young Age in Hormone Receptor Positive Breast Cancer

Gespeichert in:

Bibliographische Detailangaben
Zeitschriftentitel: BioMed Research International
Personen und Körperschaften: Lee, Minna K., Varzi, Leo A., Chung, Debra U., Cao, Minh-an, Gornbein, Jeffrey, Apple, Sophia K., Chang, Helena R.
In: BioMed Research International, 2015, 2015, S. 1-6
Format: E-Article
Sprache: Englisch
veröffentlicht:
Hindawi Limited
Schlagwörter:
General Immunology and Microbiology
General Biochemistry, Genetics and Molecular Biology
General Medicine
Details
Zusammenfassung: <jats:p><jats:italic>Background</jats:italic>. Studies have shown that young breast cancer patients have more advanced disease and worse survival compared to older patients. Our objective was to study disease characteristics and survival in the subset of young women with hormone receptor positive (HR+) and HER2 negative (HER2−) cancer.<jats:italic>Methods</jats:italic>. We retrospectively analyzed HR+/HER2− breast cancer patients who underwent surgery at our institution between 2002 and 2010. We compared clinical characteristics, pathology, treatment, and recurrence-free survival between younger (≤40 years) and older (&gt;40 years) patients.<jats:italic>Results</jats:italic>. Of 669 HR+/HER2− breast cancer cases, 54 (8.1%) patients were 40 years or younger. Younger patients had more luminal B subtype, high grade, poor differentiation, and increased lymphovascular invasion. Younger women were treated more often with mastectomy and adjuvant chemotherapy. Although the unadjusted recurrence-free survival at median 55-month follow-up was lower in younger women, adjusting for stage, there was no significant difference (90.7% versus 89.3%,<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.74</mml:mn></mml:math>) between groups.<jats:italic>Conclusion</jats:italic>. Younger patients with HR+/HER2− breast cancer had more advanced disease and more aggressive treatment than older patients. The unfavorable pathologic features suggest a biologically different tumor in young women. After adjusting for these factors, younger patients have a recurrence-free survival similar to older patients.</jats:p>
Umfang: 1-6
ISSN: 2314-6133
2314-6141
DOI: 10.1155/2015/325715